Some of the Pharmaceuticals intended for the treatment of minor illnesses of astronauts in space may require special packaging and reformulation to remain stable for long periods in the space environment. That's according to Dr. Putcha and her colleagues from NASA, Johnson Space Centre. Their findings, published online in The AAPS Journal suggest that some of the pharmaceuticals stored on space flights may have shorter shelf-life than they do on Earth.
Pharmaceuticals used on space flights are packed and dispensed in special flight-certified containers and stored in compact flight kits. They may be exposed to the unique environ-mental factors of space missions such as radiation and excessive vibration in addition to variations in temperature and humidity.
Scientists at the Johnson Space Centre investigated whether pharmaceuticals undergo degradation in space and, if so, which environmental variables in space may affect the stability of the medications in space. They compared physical and chemical changes in 35 formulations contained in identical pharmaceutical kits stowed on the International Space Station (ISS) and on Earth.
After stowage for 28 months in space, they found that a higher percentage of the medica-tions from each flight kit had a lower active pharmaceutical content than the controls on the ground. They also saw no variation in the temperature or humidity levels between Earth and in space.
Putcha and her colleagues suggest that exposure to the chronic low dose of ionizing radi-ation as well as repackaging of solid medications may be contributing factors for phar-maceutical stability in space.
The authors conclude: "It is important to characterize space-specific degradation products and toxicity limits using ground-based analogue environments of space that include proton and heavy ion radiation, vibration and multiple gravity conditions. This information can facilitate research for the development of space-hardy pharmaceuticals and packaging technologies."
Du B, Putcha L et al (2011). Evaluation of physical and chemical changes in pharmaceuticals flown on space missions. The AAPS Journal. DOI 10.1208/s12248-011-9270-0
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
French economist Jean Tirole wins 2014 award for “for his analysis of market power and regulation”
Britain is the top European nation for biotechnology capital raised in the first half of 2014, a vindication of the government's strategy to encourage the life sciences through incentives including tax breaks.
Scientists who discovered phenomena as different as the molecular mechanisms of pain, organic light-emitting diodes that illuminate mobile phones and a new quantum state of matter are top contenders for Nobel prizes next month, according to an annual analysis by Thomson Reuters.
The way the National Institutes of Health doles out research grants accentuates booms and busts in the financing of scientific research. More variety in the length of grants could help.
History suggests that scientists opposition to ideological manipulation has often been feeble. Philip Ball argues that the failings are not individual but institutional
The prizewinning science of banana-skin slips, seeing Jesus in toast and dogs aligning themselves with magnetic fields lines when relieving themselves
Most Americans lack a basic understanding of science
Tired of waiting for a cure for breast cancer, a coalition of activists now leans hard on Congress to steer money to particular research projects. Critics say that approach may miss promising leads.
This year's winners include a cartoonist, a documentarian, a leader in the legal fight for gay marriage, a saxophonist, mathematicians and scientists, poets, lawyers and advocates.
So, you want to be a science professor? Good luck. Highly educated, relatively low-paid postdoctoral fellows may drive U.S. biomedical research, but they're training for jobs that don't exist.